Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,864 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Alzheimer Disease
Interventions: Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 65
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more

Conditions: Obesity, Overweight
Interventions: Lifestyle Modification Intervention, Balanced Calorie Deficit Eating Plan, Ad Libitum Whole Food Plant-Based Eating Plan; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes, New Onset
Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 9 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Orthopoxviral Disease, Smallpox, Monkey Pox
Interventions: ST-246 Days 1 - 3, ST-246 Days 11 - 13; Drug
Lead sponsor: SIGA Technologies; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Prostate Cancer, Prostate Disease
Interventions: Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions: Somatropin (DNA origin); Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 5 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prematurity, Respiratory Distress Syndrome, Apnea of Prematurity
Interventions: continuous positive airway pressure, nasal intermittent positive pressure ventilation; Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: Up to 6 Months
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Suicidal Ideation
Interventions: Treatment; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 18 Years and older
Enrollment: 864 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions: OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist; Drug · Combination Product · Other
Lead sponsor: Epkin; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Beverly Hills, California • Santa Monica, California • Houston, Texas

Conditions: Muscle Mass
Interventions: Strength Training, Wait first, then strength training; Behavioral · Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis
Interventions: Inhaled 7% HS (NaCl) home treatment; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Participants
Interventions: TAK-954, Itraconazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Generalized Myasthenia Gravis
Interventions: Satralizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 3 more

Conditions: Cannabis Use, Cannabis Dependence, Cannabis Use Disorder, Cannabis Abuse, Cannabis Intoxication, Cannabis Smoking, Cannabis Withdrawal, Cannabis-Related Disorder, Cannabis Abuse, in Remission, Cannabis Abuse, Episodic Use, Marijuana, Marijuana Abuse, Marijuana Use, Marijuana Smoking, Marijuana Dependence, Marijuana User, Marijuana-Related Disorder, Marijuana Use Disorder, Addiction, Addiction, Substance, Substance Use, Substance Use Disorders, Substance Dependence, Substance Abuse, Substance Related Problem, Substance Abuse Drug Chronic
Interventions: Contingency Management, Elastic Net Regression; Behavioral · Device
Lead sponsor: Indiana University; Other
Eligibility: 14 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Delirium
Interventions: ED Delirium Screening and Detection Program (ED-DDP); Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 65 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Telehealth; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 80 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions: ELI-002 2P; Drug
Lead sponsor: Elicio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Active tDCS, Sham tDCS; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg; Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Obesity Prevention
Interventions: Diet and exercise, Lifestyle Intervention, Exercise; Behavioral
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Sezary Syndrome, Mycosis Fungoides
Interventions: Mogamulizumab, LD TSEBT; Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Lymphocytic Leukemia
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 10 more

Search by objective public record fields.

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Remotely Delivered Behavioral Weight Loss Using an Ad Libitum Plant-Based Diet Versus a Balanced Calorie Deficit Diet

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Phase I Trial of an Investigational Small Pox Medication

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Clinical Trial of Growth Hormone in MPS I, II, and VI

CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure

Digital Narrative Bibliotherapy as a Scalable Intervention for Suicidal Thoughts

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Strength Training Response of Muscle in GLP-1 Users

Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis

A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Neuroimaging of Adolescent Cannabis Use Treatment

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Determining the Preliminary Efficacy of the Emergency Department Delirium Screening and Detection Program

Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer

Deprescribing Tamsulosin in Older Men

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD

Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy